Business
Hyperfine Announces Presentation of Initial Data from Observational Clinical Studies Evaluating the Use of Portable MR Brain Imaging for Alzheimer's Patients
Two poster presentations at AAIC provide early evidence of the value of ultra-low-field Swoop® system MR brain images in ARIA-E detection and morphography
About this update from Hyperfine, Inc.
[{"type":"text","content":"\nTwo poster presentations at AAIC provide early evidence of the value of ultra-low-field Swoop® system MR brain images in ARIA-E detection and morphography evaluation in patients with Alzheimer's disease\n\n\n PHILADELPHIA--(BUSINESS WIRE)--\nHyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the presentation of data using the Swoop system to image patients with Alzheimer’s disease including initial data from the CARE PMR study. The data was presented at the 2024 Alzheimer’s Association International Conference (AAIC) in Philadelphia from July 28 to August 1.\n\n\nThe CARE PMR (Capturing ARIA Risk Equitably with Portable MR) study is a collection of data from multiple sites assessing the clinical utility and workflow benefits of using Swoop® system images to detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy. These investigator-initiated observational studies aim to provide insights into the potential of ultra-low-field, portable MR brain imaging to enhance care for patients with Alzheimer's disease across many sites of care.\n\n\nAt the conference, researchers from Washington University in St. Louis, a center actively enrolling patients in the CARE PMR study, presented a poster titled \"Advanced Imaging Modalities for ARIA Detection and Treatment Efficacy Monitoring in Lecanemab Therapy for Alzheimer's Disease: A Collaborative Prospective Study.\" The poster, authored by Jude-Patrick Nnamdi Okafor, MD, et al., reported data on sixteen patients. Notably, one participant exhibited \"evidence of hyperintensity on FLAIR, consistent with ARIA-E,” which was deemed “well detected at low field strength.”\n\n\nResearchers from Massachusetts General Hospital virtually presented a poster titled \"Portable, Low-field MRI for Alzheimer’s Disease,\" authored by W. Taylor Kimberly, MD, PhD, et al. This poster focused on the quantitative assessment of ultra-low-field MRI images compared to conventional high-field MR images in evaluating brain morphometry in Alzheimer's patients. The study highlighted a strong agreement in volumes between conventional high-field MR images and low-field MR images. The poster concl...